As the supply of fentanyl gets more restricted, just as easily synthesized nitazines (up to 40X more potent than fentanyl) are contaminating the drug supply. So far this is a minor issue in the Northeast USA, but we saw from Philadelphia that the xylazine to medotomidine transition took less than a year! How many are seeing nitazines showing up in their regions?
Kevin A. Sevarino, MD, PhD
Associate Clinical Professor of Psychiatry, Yale School of Medicine
Board Certified in Psychiatry and Addiction Medicine
Medical Director, American Academy of Addiction Psychiatry
HIFA profile: Dr. Sevarino earned his MD, CM at McGill Faculty of Medicine and PhD in molecular biology at the University of Connecticut Health Center. He trained in psychiatry at the Yale University School of Medicine. He was Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System from Dec. 2004 through Aug. 2017. He was consulting psychiatrist to Gaylord Hospital, Wallingford from 1999 – 2009, and again 2017-2023. He now works as per diem psychiatrist at Hartford Healthcare – Rushford. His particular expertise is in treatment of the dually-diagnosed and non-opiate pharmacological management of chronic pain. He is Associate Clinical Professor of Psychiatry, Yale University School of Medicine. He serves as Medical Director for the American Academy of Addiction Psychiatry (AAAP), is a past president of that organization, and co-directs AAAP’s Advanced Addiction Psychopharmacology course. He is a member of the HIFA working group on opioids. https://www.hifa.org/support/members/kevin https://www.hifa.org/projects/mental-health-meeting-information-needs-su... nick.s.s AT hotmail.com